I-MAB ADS overview

Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025 Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohort Strong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical...

ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB), a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in 24 th Annual Needham Virtual Healthcare Conference, being held April 7-10, 2025. Details are as follows: 24 th Annual Needham Virtual Healthcare Conference Conference Date: April 7-10, 2025 Format: Company Presentation and...

ROCKVILLE, Md., March 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), announced today that on March 19, 2025 it received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement under the Nasdaq Listing Rules (the “Listing Rules”). Based on the closing bid price of the Company’s listed...

Enrollment completed ahead of schedule in the first dose expansion cohort Momentum continues with first patient dosed in the second expansion cohort Topline results from the 40-patient dose expansion study expected in 1H 2026 Phase 1b dose escalation data expected to be presented in 2H 2025 ROCKVILLE, Md., March 07, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the...

ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision immune-oncology agents for the treatment of cancer, today announced that members of I-Mab’s management will participate in one-on-one meetings at the Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday and Wednesday, March 11-12, 2025. About I-Mab I-Mab (NASDAQ: IMAB) is a US-based, global...

ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in Oppenheimer’s 35 th Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025. Details are as follows: Oppenheimer’s 35 th Annual Healthcare Life Sciences Conference Conference...

Encouraging objective responses were observed in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR), mainly in patients previously treated with checkpoint inhibitors Phase 1 dose-escalation data demonstrated that ragistomig monotherapy can be safely administered through the highest planned doses Data will be presented at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO2024) in a poster session scheduled for June 1, 2024 at 9:00...

LOS ANGELES, CA / ACCESSWIRE / September 1, 2022 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofI-Mab ("I-Mab" or "the Company") (NASDAQ:IMAB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. I-Mab admitted in a August 16, 2022, SEC filing that collaboration partner...